Biotech Startups

Externa develops biologics using genetic code expansion, a technology aimed at incorporating synthetic amino acids into proteins of any type and size. The company positions its platform for partnerships in protein and biologics development.

1 investor

Exubrion Therapeutics develops veterinary therapies using conversion electron therapy from Tin-117m to treat pain and inflammation in companion animals. Its initial product, Synovetin OA, is a minimally invasive intra-articular injection for canine elbow osteoarthritis, marketed to veterinarians and pet owners.

1 investor

Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.

1 investor

EyeD Pharma develops pharmaceutical treatments focused on ophthalmology, particularly for glaucoma and related eye conditions. The company serves ophthalmologists and eye care professionals in treating patients with vision-related diseases.

1 investor

Eyexora is a pharmaceutical company focused on ophthalmology and eye care treatments, serving patients and healthcare providers in the therapeutic and biologics space. The company develops and commercializes therapies for conditions including glaucoma and geographic atrophy.

1 investor

Eywa Pharma develops and manufactures generic drugs across multiple therapeutic areas and dosage forms, including tablets, capsules, and oral suspensions, for patients and pharmacies. It sells products under the Eywa label in the U.S. and the Zista name in the UK, with development in Chennai, India and manufacturing in Cranbury, New Jersey.

1 investor

FREST is a Japanese biotech venture developing RNA editing technology (RNA editing nucleic acids) that edits gene structure at the mRNA level to create nucleic acid drugs for genetic and currently untreatable diseases. The company partners with medical professionals, researchers, and pharmaceutical companies to apply this drug discovery technology.

1 investor

Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases. Its pipeline addresses body composition and broader metabolic health rather than weight loss alone, serving patients with obesity and cardiometabolic comorbidities.

1 investor

Farment Bio Solutions develops fermentation-based biological products that increase nutrient availability in soil and reduce farmers' reliance on chemical fertilizers. The company serves agricultural producers seeking sustainable, cost-effective alternatives to conventional farming inputs.

1 investor

FATRO is an Italian veterinary pharmaceutical company that researches, develops, and manufactures animal-health drugs and vaccines, along with feed additives and medicated premixes. Founded in 1947 and based in Bologna, it serves veterinarians and the livestock and companion-animal sectors, exporting its products to over 90 countries.

1 investor

Fauna Systems develops biobots (programmable biological systems) that operate autonomously in complex environments. The company's work, based on xenobot research, creates living assemblies derived from cells capable of movement, self-powering, environmental sensing, and collective behavior for applications in science and medicine.

1 investor

FBB Biomed builds an analytics platform that uses blood RNA-seq data to quantify gene activity across the biological systems involved in a patient's chronic disease. It serves diagnostic labs offering RNA-based monitoring tests and biopharma companies stratifying trial participants and measuring individual treatment response.

1 investor

FemtoFluidics is an early-stage company positioning around drug discovery, with a tagline referencing applying Moore's Law-style scaling to the field. The site is a pre-launch page and provides limited concrete detail about the product.

1 investor

Fennec Pharmaceuticals develops treatments for cisplatin-induced hearing loss, a side effect of cancer chemotherapy. The company serves cancer patients undergoing treatment with cisplatin-based drugs.

1 investor

Ferric Contrast develops iron-based MRI contrast agents intended to produce high-quality magnetic resonance images of the brain, vasculature, liver, kidneys, and cancer-related tumors. The company positions its agents as safer diagnostic tools for use by physicians.

1 investor

Developed a next-generation iron chelator for iron overload in transfusion-dependent anemia; acquired by Shire in 2012.

1 investor

Ferrosan Medical Devices manufactures medical devices used in surgical procedures with a focus on product quality, safety, and improved surgical outcomes. The company operates with sustainability commitments across environmental, social, and governance areas, including renewable energy use and emission reduction targets.

1 investor

Ferryx develops next-generation probiotics aimed at improving gut health for people experiencing active flare-ups of gut conditions. A 2019 spin-out from the University of Bristol, the company works to bring these probiotics into commercial production.

1 investor

Fertiga is a biotech company that develops diagnostic tools to improve IVF success rates. The company's Aurora niPCT™ is a non-invasive diagnostic tool designed to identify the most viable oocytes for fertility treatments, with a mission to make assisted reproduction more effective and accessible.

1 investor

Fertilis designs precision medical devices for in vitro fertilization (IVF) procedures, specifically instruments that reduce mechanical stress on embryos and reduce the technical burden on embryologists. The company develops tools to enhance embryologist expertise and improve clinical outcomes rather than replace human expertise in fertility treatment.

1 investor

Figura Analytics develops platform technology for the characterisation of nanomaterials, biomarkers, pharmaceuticals, and environmental pollutants. Spun out in January 2021, the company applies its analytical technology across multiple sectors.

1 investor

1 investor

FimmCyte develops targeted immunotherapies for fibro-inflammatory diseases, with a focus on conditions like endometriosis affecting women. The company aims to create disease-modifying treatments for chronic diseases impacting women's health.

1 investor

Find Therapeutics is a clinical-stage biopharmaceutical company developing therapies to treat demyelinating diseases, particularly multiple sclerosis and related conditions affecting myelin repair. The company was founded in 2020 and is based in Canada with backing from multiple life sciences investors.

1 investor